trending Market Intelligence /marketintelligence/en/news-insights/trending/rrbf6zbmer7n2x8mhw4zwg2 content esgSubNav
In This List

EyeGate Pharmaceuticals receives Nasdaq noncompliance notice

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


EyeGate Pharmaceuticals receives Nasdaq noncompliance notice

Eyegate Pharmaceuticals Inc. received a notice from the Nasdaq Stock Market for failing to meet the $1 minimum bid price listing requirement.

To regain compliance, the closing bid price of the company's common stock must reach at least $1 per share for a minimum of 10 consecutive business days. The Waltham, Mass.-based pharmaceutical company has 180 days, or until Sept. 17, to achieve compliance.

If EyeGate fails to meet compliance by the deadline, it may be granted a second 180-day compliance period.

The company previously received a Nasdaq noncompliance notice for failing to meet the listing requirement of a minimum $2.5 million shareholders equity.

EyeGate is a clinical-stage specialty pharmaceutical company which focuses on treating diseases and disorders of the eye.